Michael L. Fantozzi
Member/Incoming Managing Member | Managing Member, Boston Office | Chair, Corporate, Tax, Private Client & Immigration Division
+1.617.348.1640
Michael is the incoming Managing Member of Mintz and a corporate attorney advising public and private companies, boards of directors, founders, and investors on mergers and acquisitions, capital markets transactions, corporate governance matters, and other strategic business issues. He has served as counsel on transactions ranging from middle-market acquisitions to multibillion-dollar public company deals, helping organizations navigate pivotal moments in their growth and evolution.
Michael’s practice spans the life sciences, health care, technology, industrial, manufacturing, and financial services sectors. He represents clients in acquisitions, divestitures, public offerings, equity and debt financings, SPAC transactions, and complex strategic transactions.
His experience includes advising Azenta Life Sciences in the $3 billion sale of its Semiconductor Solutions business to Thomas H. Lee Partners; The Metals Company (formerly DeepGreen Metals) in its $2.9 billion business combination with Sustainable Opportunities Acquisition Corporation; Quantum-Si in its $1.46 billion business combination; Butterfly Network in its $1.5 billion business combination; and QIAGEN in its proposed $12.5 billion sale to Thermo Fisher Scientific. He has also represented companies including Vertex Pharmaceuticals, John Hancock Financial Network, Fidelity, and C&S Wholesale Grocers, among others.
Michael is highly regarded for his practical judgment and business-minded approach and understands the complex business priorities, risk tolerance, and commercial realities facing management teams, boards, and investors. As a result, clients often turn to him not only for legal advice, but also for counsel on complex business decisions, management transitions, and organizational challenges.
In addition to his practice, Michael plays a significant role in firm leadership, serving as Managing Member of the Boston office, Division Head of the Corporate, Tax, Private Client, and Immigration Practices, and a member of the firm’s Policy and Compensation Committees. Michael has been appointed Mintz’s next Managing Member, a role he will assume on July 1, 2027.
Through these roles, he has helped shape Mintz’s strategic direction, strengthen its leadership, and advance its long-term priorities. His leadership style reflects the same principles that guide his client work: listening carefully, understanding the issues at hand, and building solutions that meet the needs of the people and organizations he serves.
Michael is the incoming Managing Member of Mintz and a corporate attorney advising public and private companies, boards of directors, founders, and investors on mergers and acquisitions, capital markets transactions, corporate governance matters, and other strategic business issues. He has served as counsel on transactions ranging from middle-market acquisitions to multibillion-dollar public company deals, helping organizations navigate pivotal moments in their growth and evolution.
Experience
Mergers & Acquisitions
- Hyperfine, Inc.'s (Nasdaq: HYPR) business combination, valued at $580 million, with Liminal Sciences and the SPAC, HealthCor Catalio Acquisition Corp.
- The Metals Company’s (Nasdaq: TMC) (formerly DeepGreen Metals) business combination, valued at $2.9 billion, with the SPAC, Sustainable Opportunities Acquisition Corporation
- Azenta Life Sciences' (Nasdaq: AZTA) (formerly Brooks Automation, Inc.) $3 billion sale of its Semiconductor Solutions business to private equity firm Thomas H. Lee Partners, L.P.
- Optum’s acquisition of Atrius Health
- Quantum-SI’s (Nasdaq: QSI) $1.46 billion business combination with the SPAC, HighCape Capital Acquisition Corp.
- Butterfly Network’s (NYSE: BFLY) $1.5 billion business combination with the SPAC, Longview Acquisition Corp.
- QIAGEN in its proposed $12.5 billion sale to Thermo Fisher Scientific
- Brooks Automation’s approximately $450 million purchase of genomics service provider Genewiz Group
- Brooks Automation’s $675 million sale of its semiconductor cryogenics business to Edwards Vacuum LLC (a member of the Atlas Copco Group)
- John Hancock Financial Network’s sale of Signator Investors to Advisor Group
- Connance’s sale to Waystar Health
- Optum’s purchase of Reliant Medical Group
- Fidelity’s purchase of a software solutions company
- C&S Wholesale Grocers’ purchase of the assets of Davidson Co., Inc.
- Brooks Automation’s $127 million purchase of BioStorage Technologies
- John Hancock Financial Network’s purchase of the assets of Transamerica Financial Advisors
- Naurex’s sale to Allergan
- Leerink Swann’s sale of the assets of Leerink Swann Consulting to NCI Healthcare
- John Hancock Financial Network’s purchase of Symetra Investment Services
- C&S Wholesale Grocers’ purchase of the assets of Associated Wholesalers
- Humedica’s sale to UnitedHealth Group
- Piramal Healthcare Limited’s $635 million purchase of Decision Resources Group
- iMDsoft’s $60 million sale to TPG
- Ion Torrent Systems’ $725 million sale to Life Technologies
- Amicas’ $267 million sale to Merge Healthcare
- Vertex Pharmaceuticals’ $400 million purchase of ViroChem Pharma
- iBasis’ $100 million sale to Royal KPN
- Qiagen’s $1.6 billion purchase of Digene Corporation
Public Offerings
- Vertex Pharmaceuticals in over $2.5 billion in equity and debt offerings
Michael also serves as counsel to Brooks Automation and John Hancock Life Insurance Company. Private company clients include C&S Wholesale Grocers, LAM Therapeutics and W.E. Aubuchon Co.
Case Studies
Case Study
News & Press
Mintz's Boston Office Head to Succeed Longtime Firm Leader
September 29, 2026|
Mintz Gets a New Leader, and This Time He's a Bostonian
September 29, 2026|
After 18 Years, Mintz Chooses New Leader
September 29, 2026|
Mintz Named a Law360 2022 Powerhouse in Massachusetts
August 8, 2022|
Massachusetts Powerhouse: Mintz
August 8, 2022|
Massachusetts Powerhouse: Mintz
August 5, 2021|
Mintz Recognized as 2021 Massachusetts Powerhouse by Law360
August 4, 2021|
Mintz Publishes In-Depth Report Breaking Down the SPAC Surge
March 19, 2021|
Mintz Atty On Steering Quantum-Si's $1.46B Go-Public Deal
February 23, 2021|
Mintz Advises Quantum-SI in $1.46 Billion SPAC Merger
February 19, 2021|
Massachusetts Powerhouse: Mintz Levin
August 30, 2018|
Garrett M. Winslow Elevated to Member of Mintz
May 18, 2017|
Mintz Represents Naurex Inc. in Merger with Allergan PLC
July 29, 2015|
Mintz and LearnLaunch Announce Partnership
February 21, 2014|
Events & Speaking
Let's Talk SPACs - SPACs Session 2: de-SPAC – So Now You’re a Public Company
HUB International
Webinar
New England Healthcare Executive Network Meeting
Special Purpose Acquisition Company ("SPAC") Impact On Medtech
Webinar
Michael is the incoming Managing Member of Mintz and a corporate attorney advising public and private companies, boards of directors, founders, and investors on mergers and acquisitions, capital markets transactions, corporate governance matters, and other strategic business issues. He has served as counsel on transactions ranging from middle-market acquisitions to multibillion-dollar public company deals, helping organizations navigate pivotal moments in their growth and evolution.
Recognition & Awards
Best Lawyers in America: Boston - Corporate Governance Law Lawyer of the Year (2025)
Best Lawyers in America: Securities/Capital Markets Law (2007 – 2026); Corporate Law (2007 – 2026); Corporate Governance Law (2007 - 2026).
Included on the Massachusetts Super Lawyers list: Securities & Corporate Finance (2004 – 2006, 2008 – 2018, 2022 – 2023)
Recommended by The Legal 500 United States for Capital Markets: Equity (2020 – 2022, 2024)
Recommended by The Legal 500 United States for M&A: Middle-Market (2016 – 2017, 2020 – 2022, 2024, 2026)
Recent Insights
Mintz's Boston Office Head to Succeed Longtime Firm Leader
September 29, 2026|
After 18 Years, Mintz Chooses New Leader
September 29, 2026|
